VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

VYNE Therapeutics announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022. CEO David Domzalski will present at 12:30 p.m. ET and is available for one-on-one meetings with investors. VYNE focuses on innovative therapies for immuno-inflammatory conditions using its unique bromodomain and extra-terminal domain platform, including lead programs VYN201 and VYN202. A replay of the presentation will be accessible on VYNE's website for 90 days.

September 13, 2022

BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24^th Annual Global Investment Conference (Hybrid) on September 13, 2022. Management will also be available for one-on-one meetings with investors.

H.C. Wainwright 24^th Annual Global Investment Conference – Presentation Details

Date:	Tuesday, September 13, 2022
Time:	12:30 p.m. ET
Format:	Company Presentation
Presenter:	David Domzalski, President and Chief Executive Officer of VYNE
Webcast Link:	To attend, please register here.
	*a replay will be available on the VYNE website for 90 days following the presentation

Please contact your H.C. Wainwright & Co. representative if you would like to schedule a one-on-one meeting during the conference.

For more information about the H.C. Wainwright 24^th Annual Global Investment Conference, please refer to the conference website.

About VYNE Therapeutics Inc.

VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

FAQ

When is VYNE participating in the H.C. Wainwright 24th Annual Global Investment Conference?

VYNE is participating in the conference on September 13, 2022.

Who is presenting for VYNE at the conference?

David Domzalski, the President and CEO of VYNE, will be presenting.

What time is VYNE's presentation at the conference?

VYNE's presentation is scheduled for 12:30 p.m. ET.

How can investors access the VYNE presentation?

Investors can attend the presentation via the webcast link provided in the press release.

What is the focus of VYNE Therapeutics?

VYNE focuses on developing innovative therapies for immuno-inflammatory conditions.

How long will the VYNE presentation replay be available?

The replay will be available for 90 days following the presentation.